Stephens Issues Pessimistic Forecast for OptimizeRx (NASDAQ:OPRX) Stock Price

OptimizeRx (NASDAQ:OPRX) had its price target reduced by investment analysts at Stephens from $20.00 to $17.00 in a research note issued on Monday,Benzinga reports. The firm currently has an “equal weight” rating on the stock. Stephens’ target price would indicate a potential upside of 11.99% from the stock’s previous close.

Other equities analysts have also issued reports about the stock. JMP Securities raised their target price on shares of OptimizeRx from $20.00 to $23.00 and gave the stock a “market outperform” rating in a research report on Friday, October 10th. Stifel Nicolaus raised their target price on shares of OptimizeRx from $16.00 to $18.00 and gave the company a “buy” rating in a report on Friday, August 8th. Weiss Ratings restated a “sell (d-)” rating on shares of OptimizeRx in a research report on Wednesday, October 8th. Citigroup reissued an “outperform” rating on shares of OptimizeRx in a research report on Friday, October 10th. Finally, Zacks Research downgraded shares of OptimizeRx from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 7th. Seven analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, OptimizeRx presently has an average rating of “Moderate Buy” and an average price target of $16.88.

OptimizeRx Stock Performance

Shares of OPRX stock opened at $15.18 on Monday. OptimizeRx has a 12-month low of $3.78 and a 12-month high of $22.25. The company has a current ratio of 2.57, a quick ratio of 2.57 and a debt-to-equity ratio of 0.21. The business’s 50 day moving average is $18.65 and its two-hundred day moving average is $15.45. The company has a market capitalization of $282.97 million, a P/E ratio of -28.11 and a beta of 1.24.

OptimizeRx (NASDAQ:OPRX) last issued its quarterly earnings data on Thursday, November 6th. The company reported $0.20 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.17. The company had revenue of $26.07 million during the quarter, compared to analyst estimates of $23.83 million. OptimizeRx had a positive return on equity of 4.50% and a negative net margin of 9.42%. OptimizeRx has set its FY 2026 guidance at EPS. FY 2025 guidance at EPS. Analysts expect that OptimizeRx will post -0.33 EPS for the current fiscal year.

Insider Buying and Selling at OptimizeRx

In related news, Director Patrick D. Spangler sold 11,120 shares of OptimizeRx stock in a transaction dated Thursday, August 28th. The stock was sold at an average price of $17.49, for a total transaction of $194,488.80. Following the sale, the director directly owned 44,215 shares of the company’s stock, valued at $773,320.35. This trade represents a 20.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Stephen L. Silvestro sold 1,620 shares of the company’s stock in a transaction on Friday, October 3rd. The shares were sold at an average price of $18.75, for a total value of $30,375.00. Following the completion of the sale, the chief executive officer owned 188,916 shares in the company, valued at $3,542,175. This trade represents a 0.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 5.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On OptimizeRx

A number of hedge funds and other institutional investors have recently bought and sold shares of OPRX. Nisa Investment Advisors LLC raised its position in OptimizeRx by 600.0% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,121 shares of the company’s stock valued at $29,000 after purchasing an additional 1,818 shares during the last quarter. Quantbot Technologies LP bought a new position in shares of OptimizeRx in the second quarter valued at about $44,000. BNP Paribas Financial Markets lifted its position in OptimizeRx by 119.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock worth $55,000 after buying an additional 2,215 shares in the last quarter. USA Financial Formulas acquired a new position in OptimizeRx during the 3rd quarter worth about $131,000. Finally, Wesbanco Bank Inc. bought a new stake in OptimizeRx during the 3rd quarter worth about $205,000. 76.47% of the stock is owned by institutional investors and hedge funds.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.